Skip to main content

CME Symposium: Managing LDL-C to Reduce Cardiovascular Disease Risk: Defining Best Clinical Practice

By: PRLog
This CME Symposium takes place on Sunday, November 11, 2018, from 7:00 PM- 9:00 PM at the InterContinental Hotel, Grand Ballroom, 505 North Michigan Avenue, Chicago, Illinois
CHICAGO - Sept. 5, 2018 - PRLog -- Click to register online

Statin trials have demonstrated atherosclerotic cardiovascular disease (ASCVD) risk reduction with progressively lower levels of LDL-cholesterol (LDL-C). The 2010 meta-analysis of statin trials by the Cholesterol Treatment Trialists Collaboration (CTTC) revealed a 22% relative risk reduction in major vascular events per 39 mg/dL reduction in LDL-C that is consistent across baseline LDL-C levels, down to less than 77 mg/dL. Nonstatin drugs such as ezetimibe and PCSK9 inhibitors further lower LDL-C levels and further reduce cardiovascular risk when added to statins, while demonstrating safety at very low LDL-C levels. A meta-analysis for statins and nonstatins (Sabatine et al., 2018) has indicated virtually the same magnitude of risk reduction as demonstrated in the CTTC analysis in which the starting LDL-C was nearly twice as high. In this recently published analysis, there is a consistent relative risk reduction in major vascular events, starting as low as a median of 63 mg/dL and achieving levels as low as a median of 21 mg/ dL, with no observed offsetting adverse effects. An abundance of data now provide support for the concept that for LDL-C lowering, "lower is better", and "lowest is best". In this program, an expert faculty will discuss the evidence and recommendations for managing LDL-C in patients with ASCVD, familial hypercholesterolemia (FH), diabetes, and those at increased cardiovascular risk without ASCVD.

Chair:
Pamela Morris, MD

Associate Professor of Medicine
Medical University of South Carolina
Charleston, South Carolina

Faculty:
Christie Ballantyne, MD

Professor of Medicine
Baylor College of Medicine
Houston, Texas

Peter Jones, MD
Associate Professor of Medicine
Baylor College of Medicine
Houston, Texas

Marc Sabatine, MD, MPH
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

James Underberg, MD, MS
Clinical Assistant Professor of Medicine
New York University School of Medicine
New York, New York

Voxmedia International gratefully acknowledges the educational grant supported by Amgen.

This educational activity is intended for cardiovascular clinicians.

Pre-registration is for planning purposes only.

For additional CME activities and online cme courses visit CMEPlanet

Contact
Voxmedia
***@voxmedia.us

Photos: (Click photo to enlarge)

Voxmedia Logo 2018 AHA CME Symposium LDL-C Lipid

Read Full Story - CME Symposium: Managing LDL-C to Reduce Cardiovascular Disease Risk: Defining Best Clinical Practice | More news from this source

Press release distribution by PRLog

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.